MicroPort® NeuroTech Attends CINS 2016

Beijing, China – From December 9 to December 11, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") attended the 2nd Annual Conference of Chinese Interventional Neuroradiology Society of Chinese Stroke Association ("CINS 2016") to display APOLLO Intracranial Stent System ("APOLLO"). The CINS 2016 was hosted by Chinese Stroke Association and Chinese Interventional Neuroradiology Society of Chinese Stroke Association, and many domestic and international leading figures in the neurointervention field were invited to attend the event for academic exchange.
In the past year, there has been new advancement in China's neurointervention field in terms of technical training, quality control, clinical studies, academic theories, science popularization, and organization development. There also emerges new evidence for the stent treatment of carotid artery stenosis and new breakthroughs in using Flow Diverter to treat arterial aneurysm.
In the academic symposium of the CINS 2016, Professor Kangning Chen of the Southwest Hospital of the Third Military Medical University released the follow-up result of VAOS stent implantation in the report regarding the long-term follow-up results of multi-center studies of stent treatment of vertebral artery stenosis. Professor Chen also shared the mid-term outcome of the pre-market clinical trial of the vertebral artery drug stent in-house developed by MicroPort® NeuroTech, which was well received by attendees.
Professor Ning Ma of Beijing Tian Tan Hospital of Capital Medical University released the preliminary one-year follow-up result of "AIRE-China" - a clinical study in China of evaluating APOLLO in treating symptomatic intracranial stenosis, in the report of the long-term follow-up results of multi-center studies of stent treatment of intracranial arterial stenosis.
Independently designed and developed by MicroPort® NeuroTech, APOLLO was launched in the China market in 2005. It is China's first intracranial vascular stent for the treatment of ischemic cerebrovascular disease. It was awarded the second prize of Shanghai Scientific Progress Award in 2009 and was listed in the National Key New Products Scheme in 2011.